Hypertrophic Osteodystrophy

Hypertrophic osteodystrophy (HOD) is a developmental skeletal disorder of young, rapidly growing large and giant breed dogs, characterized by acute onset of lameness, pyrexia, and painful swelling of the metaphyseal regions of long bones. The disease primarily affects the distal radius, ulna, tibia, and fibula, with characteristic radiographic findings of a 'double physis' or 'double line' appearance due to irregular mineralization and sclerosis adjacent to the growth plate. HOD is considered a form of metaphyseal osteopathy, and its pathogenesis is multifactorial, involving genetic predisposition, nutritional imbalances, and possibly infectious agents. The condition is typically self-limiting but can be severely debilitating during acute episodes, and in rare cases, may lead to angular limb deformities or growth retardation. Surgical intervention is rarely required, but in severe cases with pathological fractures or angular deformities, surgical stabilization or corrective osteotomy may be indicated. The disease is also known as metaphyseal osteopathy, and it is distinct from other developmental orthopedic conditions such as panosteitis, osteochondritis dissecans, and retained cartilage cores.

The exact etiology of hypertrophic osteodystrophy remains unclear, but several factors have been implicated. Nutritional imbalances, particularly excessive calcium intake or an imbalanced calcium-to-phosphorus ratio, have been historically associated with the disease, especially in puppies fed high-calorie, high-calcium diets. Over-supplementation of calcium and vitamin D may disrupt normal endochondral ossification, leading to metaphyseal ischemia and necrosis. Infectious agents, such as canine distemper virus, have been proposed as a trigger, as viral inclusion bodies have been identified in some affected dogs, and vaccination with modified-live distemper vaccines has been temporally associated with the onset of HOD in certain cases. However, a direct causal link has not been definitively established. Genetic predisposition is likely, as certain breeds, including Weimaraners, Great Danes, Boxers, and Irish Setters, are overrepresented, suggesting an inherited susceptibility. Additionally, a dysregulated inflammatory response, possibly due to an exaggerated immune reaction to bacterial endotoxins or viral antigens, may contribute to the systemic signs and metaphyseal inflammation. The disease is characterized by microvascular thrombosis and infarction in the metaphyseal region, leading to bone necrosis, inflammation, and subsequent periosteal new bone formation. The exact cellular mechanisms involve endothelial damage, activation of the coagulation cascade, and release of pro-inflammatory cytokines, resulting in ischemic injury to the growth plate and adjacent metaphysis.

Hypertrophic osteodystrophy primarily affects young, rapidly growing large and giant breed dogs, typically between 3 and 6 months of age, although cases have been reported up to 12 months. Breeds with a high predisposition include Weimaraners, Great Danes, Boxers, Irish Setters, Labrador Retrievers, and Doberman Pinschers. There is no significant sex predilection, although some studies suggest a slight male predominance. The incidence is higher in dogs fed high-energy, high-calcium diets, and the condition is more commonly seen in puppies that are over-supplemented with calcium and vitamin D. The disease is less frequently reported in cats, and when it occurs, it is often associated with nutritional imbalances. The prevalence of HOD has decreased in recent decades due to improved awareness of proper puppy nutrition, but it remains a significant cause of lameness in large-breed puppies. The condition is often bilateral and symmetric, affecting multiple limbs simultaneously, with the distal radius, ulna, tibia, and fibula being the most commonly affected sites. The acute phase typically lasts 1-2 weeks, but recurrent episodes may occur until skeletal maturity. In severe cases, complications such as angular limb deformities, pathological fractures, and growth retardation can occur, leading to long-term orthopedic issues.

The pathophysiology of hypertrophic osteodystrophy involves a complex interplay of vascular, inflammatory, and metabolic factors. The primary event is believed to be microvascular thrombosis and infarction in the metaphyseal region of long bones, leading to ischemic necrosis of the primary spongiosa and adjacent growth plate. This ischemia results in the release of inflammatory mediators, including cytokines and prostaglandins, which cause pain, swelling, and systemic signs such as pyrexia. The necrotic bone is subsequently resorbed by osteoclasts, and there is an influx of inflammatory cells, including neutrophils and macrophages, leading to a periosteal reaction and new bone formation. Radiographically, this appears as a 'double physis' or 'double line' sign, where a radiolucent band separates the growth plate from a sclerotic metaphyseal region. Histologically, there is evidence of trabecular necrosis, hemorrhage, and fibrosis, with areas of cartilage retention and abnormal endochondral ossification. The disease may also affect the growth plate itself, leading to premature closure or irregular growth, which can result in angular limb deformities. The systemic signs, including fever and lethargy, are likely due to the release of pyrogens from the inflammatory response. The exact trigger for the microvascular thrombosis is unknown, but it may involve immune complex deposition, endotoxemia, or viral infection. The condition is self-limiting, but recurrent episodes can occur until the growth plates close, and the severity of the disease can vary from mild lameness to severe, debilitating pain.

Several intrinsic and extrinsic factors predispose dogs to hypertrophic osteodystrophy. Intrinsic factors include genetic susceptibility, as certain breeds are overrepresented, suggesting a heritable component. Age is a critical factor, as the disease occurs during the rapid growth phase, typically between 3 and 6 months. Large and giant breed dogs are more susceptible due to their rapid growth rates and larger metaphyseal areas. Extrinsic factors include nutritional imbalances, particularly excessive calcium intake, which is a well-documented risk factor. High-calorie diets that promote rapid growth also increase the risk. Over-supplementation of calcium, vitamin D, and other minerals can disrupt normal bone mineralization and contribute to the disease. Infectious agents, such as canine distemper virus, have been implicated as triggers, and vaccination with modified-live distemper vaccines has been temporally associated with the onset of HOD in some cases. Environmental factors, such as excessive exercise or trauma to the metaphyseal region, may also play a role, although they are not primary causes. Management practices, such as feeding a balanced growth diet and avoiding over-supplementation, are crucial in preventing the disease. Additionally, dogs with a history of HOD may have a higher risk of developing angular limb deformities later in life, particularly if the distal ulnar growth plate is affected.

The clinical signs of hypertrophic osteodystrophy are acute and often severe. Affected puppies present with sudden onset of lameness, which may be unilateral or bilateral, and can progress to reluctance to stand or walk. The lameness is typically shifting, affecting multiple limbs, and is accompanied by pyrexia (fever) ranging from 39.5 to 40.5°C (103-105°F). Physical examination reveals painful swelling of the metaphyseal regions of the long bones, particularly the distal radius, ulna, tibia, and fibula. The swelling is warm to the touch and may be erythematous. Palpation of the affected areas elicits a marked pain response, and the puppy may cry or become aggressive. Systemic signs include lethargy, anorexia, and depression. In severe cases, the puppy may be unable to stand, and there may be signs of systemic inflammatory response syndrome (SIRS), such as tachycardia and tachypnea. The disease is often bilateral and symmetric, and the clinical signs may wax and wane, with recurrent episodes occurring until skeletal maturity. In some cases, the disease may be subclinical, with only mild lameness and no systemic signs. Complications such as pathological fractures, angular limb deformities, and growth retardation can occur, leading to chronic lameness and functional impairment. The severity of clinical signs is variable, and some puppies may recover without long-term sequelae, while others may develop significant orthopedic problems.

The differential diagnoses for hypertrophic osteodystrophy include several developmental and acquired orthopedic conditions. Panosteitis is a common differential, characterized by shifting leg lameness in young large-breed dogs, but it typically affects the diaphysis rather than the metaphysis, and there is no fever or metaphyseal swelling. Radiographically, panosteitis shows a patchy increase in medullary bone density, whereas HOD shows a 'double physis' sign. Osteochondritis dissecans (OCD) is another differential, particularly when lameness is localized to the shoulder, elbow, or stifle, but OCD is not associated with fever or metaphyseal swelling, and radiographs show subchondral bone defects. Retained cartilage cores, also known as retained enchondral cartilage, can cause metaphyseal changes, but they are usually incidental findings and do not cause acute pain or fever. Septic arthritis or osteomyelitis can present with fever and lameness, but there is usually a history of trauma or infection, and radiographs may show lytic lesions or periosteal reaction. Radiographs and joint aspiration can help differentiate these conditions. Nutritional secondary hyperparathyroidism can cause bone pain and lameness, but it is associated with a poor diet and radiographs show generalized osteopenia. Hypertrophic osteopathy, also known as Marie's disease, is a paraneoplastic syndrome that causes periosteal new bone formation, but it occurs in older dogs with thoracic masses and is not associated with fever or growth plate changes. Other differentials include trauma, fractures, and ligament injuries, which can be ruled out by history and radiographs. A thorough diagnostic workup, including radiographs, blood work, and joint aspiration, is essential to accurately diagnose HOD and rule out other conditions.

The diagnostic algorithm for hypertrophic osteodystrophy begins with a thorough history and physical examination. The presence of acute lameness, fever, and metaphyseal swelling in a young large-breed dog should raise suspicion for HOD. The diagnostic workup should include a complete blood count (CBC), serum biochemistry profile, and urinalysis to assess for systemic inflammation and rule out other causes of fever and lameness. Radiographs of the affected limbs are essential and typically show characteristic changes, including a 'double physis' or 'double line' sign, which is a radiolucent band parallel to the growth plate, with adjacent sclerosis and periosteal new bone formation. The distal radius, ulna, tibia, and fibula are most commonly affected. In some cases, advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) may be indicated to further characterize the extent of the disease or to evaluate for complications such as angular limb deformities. Synovial fluid analysis may be performed to rule out septic arthritis, and it typically shows a non-inflammatory or mildly inflammatory fluid with normal mucin clot. In cases where the diagnosis is uncertain, a bone biopsy may be performed, but it is rarely necessary. The diagnostic algorithm should also include a thorough dietary history, as nutritional imbalances are a common predisposing factor. If the puppy has a history of over-supplementation or an unbalanced diet, this supports the diagnosis. The diagnosis is often made based on clinical signs and characteristic radiographic findings, and treatment is initiated without the need for invasive diagnostics. However, if the puppy does not respond to supportive care, further investigation may be warranted to rule out other conditions.

Laboratory findings in hypertrophic osteodystrophy are non-specific but can support the diagnosis and rule out other conditions. A complete blood count (CBC) may show leukocytosis with a left shift, indicating an inflammatory response. Mild anemia may be present due to chronic inflammation. Serum biochemistry profile may reveal elevated acute-phase proteins, such as C-reactive protein (CRP) and serum amyloid A (SAA), which are markers of systemic inflammation. Alkaline phosphatase (ALP) may be elevated due to increased bone turnover, but this is not specific. Calcium and phosphorus levels are typically within normal limits, but in cases of nutritional imbalances, they may be abnormal. Synovial fluid analysis is often performed to rule out septic arthritis. In HOD, the synovial fluid is typically non-inflammatory, with a low cell count and good mucin clot. However, in severe cases, there may be a mild increase in nucleated cell count, predominantly mononuclear cells. Bacterial culture of the synovial fluid is negative. Coagulation parameters, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), are usually within normal limits, but in severe cases with systemic inflammatory response syndrome (SIRS), there may be evidence of disseminated intravascular coagulation (DIC). Blood gas analysis may be indicated in critically ill puppies to assess for metabolic acidosis or hypoxia. Urinalysis is typically unremarkable. In cases where infectious agents are suspected, serology or PCR for canine distemper virus may be performed, but this is not routinely recommended. Overall, laboratory findings are supportive but not diagnostic, and the diagnosis is primarily based on clinical signs and radiographs.

Imaging is crucial for the diagnosis and management of hypertrophic osteodystrophy. Radiography is the primary imaging modality and typically shows characteristic changes in the metaphyseal regions of long bones. The most distinctive finding is the 'double physis' or 'double line' sign, which appears as a radiolucent band parallel to the growth plate, with adjacent sclerosis and periosteal new bone formation. This is due to ischemic necrosis of the primary spongiosa and subsequent periosteal reaction. The distal radius, ulna, tibia, and fibula are most commonly affected, but other long bones may also be involved. Radiographs should be taken in multiple views, including lateral and anteroposterior projections, to fully assess the extent of the disease. In severe cases, there may be evidence of pathological fractures or angular limb deformities. Ultrasonography may be used to assess soft tissue swelling and periosteal reaction, but it is not routinely performed. Computed tomography (CT) provides more detailed imaging of the bone and can be useful in evaluating the extent of the disease and planning surgical intervention if needed. CT can also help identify subtle changes that may not be visible on radiographs. Magnetic resonance imaging (MRI) is rarely indicated but may be useful in assessing the growth plate and surrounding soft tissues. In cases where angular limb deformities develop, advanced imaging is essential for surgical planning. Arthroscopy is not typically used for HOD, but it may be performed to rule out concurrent joint disease. Overall, radiography is the mainstay of imaging for HOD, and the characteristic findings are often sufficient for diagnosis.

Cytology and histopathology are not routinely required for the diagnosis of hypertrophic osteodystrophy, but they may be performed in atypical cases or to rule out other conditions. Synovial fluid cytology is often performed to rule out septic arthritis. In HOD, the synovial fluid is typically non-inflammatory, with a low nucleated cell count (less than 2000 cells/µL) and a good mucin clot. The cells are predominantly mononuclear, with occasional neutrophils. Bacterial culture is negative. If a bone biopsy is performed, histopathological findings include areas of trabecular necrosis, hemorrhage, and fibrosis in the metaphysis. There is evidence of abnormal endochondral ossification, with retention of cartilage and irregular mineralization. The periosteum may show reactive new bone formation. In some cases, there may be evidence of microvascular thrombosis and infarction. Special stains, such as Masson's trichrome, can help highlight fibrosis, and immunohistochemistry may be used to identify inflammatory cells. However, histopathology is rarely necessary for diagnosis, as the clinical signs and radiographic findings are usually characteristic. In cases where the disease is severe or recurrent, a biopsy may be considered to rule out other causes of metaphyseal osteopathy, such as neoplasia or infection. Overall, cytology and histopathology are not essential for the diagnosis of HOD but can be helpful in complex cases.

The treatment of hypertrophic osteodystrophy is primarily medical and supportive, with surgical intervention reserved for complications such as pathological fractures or angular limb deformities. The goals of treatment are to alleviate pain, reduce inflammation, and manage systemic signs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to control pain and inflammation, but they should be used with caution in young puppies due to the risk of gastrointestinal and renal side effects. Carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) are commonly used, but the duration of treatment should be limited to the acute phase. Corticosteroids, such as prednisone (0.5-1 mg/kg PO q24h), may be used in severe cases that do not respond to NSAIDs, but they should be used with caution due to potential adverse effects on growth. Opioid analgesics, such as tramadol (2-5 mg/kg PO q8-12h) or butorphanol (0.1-0.2 mg/kg IV/IM), may be used for severe pain. Antibiotics are not indicated unless there is evidence of secondary infection. Supportive care includes rest, confinement, and a balanced diet. Nutritional management is crucial, and the diet should be adjusted to ensure appropriate calcium and phosphorus levels, avoiding over-supplementation. In severe cases, hospitalization may be required for fluid therapy and supportive care. Surgical intervention is rarely needed, but if a pathological fracture occurs, internal fixation may be necessary. Angular limb deformities may require corrective osteotomy once the growth plates have closed. In cases of severe pain and swelling, cold therapy (cryotherapy) may be applied to the affected limbs to reduce inflammation. Physical therapy, including passive range of motion exercises, may be beneficial once the acute pain has resolved. The prognosis for HOD is generally good, with most puppies recovering without long-term sequelae, but recurrent episodes may occur until skeletal maturity.

The prognosis for hypertrophic osteodystrophy is generally good, with most affected puppies recovering fully with appropriate medical management. The acute phase typically lasts 1-2 weeks, and clinical signs usually resolve with supportive care. However, recurrent episodes may occur until the growth plates close, which can be up to 12 months of age. The long-term prognosis is excellent for most dogs, with no permanent lameness or functional impairment. However, in severe cases, complications such as angular limb deformities, pathological fractures, and growth retardation can occur, leading to chronic lameness and the need for surgical intervention. The prognosis is worse in dogs that develop angular limb deformities, particularly if the distal ulnar growth plate is affected, as this can lead to a valgus deformity of the carpus. The prognosis is also guarded in dogs that develop pathological fractures, as these may require surgical stabilization. Negative prognostic indicators include severe systemic signs, such as high fever and lethargy, and the development of complications. Early diagnosis and appropriate management, including nutritional correction and anti-inflammatory therapy, are associated with a better prognosis. Overall, the majority of dogs with HOD have a good to excellent prognosis, and most can lead normal, active lives.

Follow-up for hypertrophic osteodystrophy involves regular monitoring of clinical signs and radiographic changes. During the acute phase, the puppy should be re-evaluated every 3-5 days to assess response to treatment and adjust medications as needed. Once the acute signs have resolved, follow-up examinations should be scheduled every 2-4 weeks until the growth plates close. Radiographs should be repeated at 4-8 week intervals to monitor for the resolution of metaphyseal changes and to detect any complications, such as angular limb deformities or premature growth plate closure. If angular limb deformities are detected, more frequent monitoring may be necessary, and referral to a veterinary surgeon may be indicated. The puppy should be kept on a balanced growth diet, and over-supplementation should be avoided. Activity should be restricted during the acute phase, with a gradual return to normal activity as the puppy improves. Physical therapy, including controlled exercise and passive range of motion exercises, may be recommended to maintain joint mobility and muscle mass. Long-term follow-up is recommended to monitor for the development of osteoarthritis, particularly if the growth plates are affected. In dogs that undergo surgical correction of angular limb deformities, follow-up radiographs should be taken at 4, 8, and 12 weeks postoperatively to assess bone healing and alignment. The owner should be educated on the signs of recurrence and the importance of maintaining a proper diet and exercise regimen.

Clinical pearls for hypertrophic osteodystrophy include recognizing the characteristic 'double physis' sign on radiographs, which is pathognomonic for the disease. Early diagnosis and treatment are crucial to minimize pain and prevent complications. Nutritional counseling is essential, and owners should be advised to feed a balanced growth diet and avoid calcium and vitamin D supplementation. NSAIDs should be used with caution in young puppies, and the lowest effective dose should be used for the shortest duration possible. Corticosteroids may be used in severe cases, but they should be avoided if possible due to potential adverse effects on growth. Supportive care, including rest and cold therapy, can help reduce pain and swelling. Pitfalls include misdiagnosing HOD as panosteitis or septic arthritis, which can lead to inappropriate treatment. Overuse of NSAIDs can cause gastrointestinal ulceration and renal damage, so monitoring for adverse effects is important. Failure to address nutritional imbalances can lead to recurrent episodes and complications. In severe cases, failure to recognize and treat pathological fractures or angular limb deformities can result in permanent lameness. Surgical intervention should be avoided during the acute phase, as the bone is fragile and prone to implant failure. When surgical correction of angular limb deformities is indicated, it should be delayed until the growth plates have closed to prevent recurrence. Overall, a thorough understanding of the disease and its management is essential for successful outcomes.

Current drug protocols for hypertrophic osteodystrophy focus on pain management and anti-inflammatory therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of treatment. Carprofen (2.2 mg/kg PO q12h) is commonly used, but it should be used with caution in puppies due to the risk of gastrointestinal and renal side effects. Meloxicam (0.1 mg/kg PO q24h) is another option, but it is not approved for use in dogs less than 6 months of age in some countries. For severe pain, opioid analgesics such as tramadol (2-5 mg/kg PO q8-12h) or butorphanol (0.1-0.2 mg/kg IV/IM) may be used. In cases of severe inflammation that do not respond to NSAIDs, corticosteroids such as prednisone (0.5-1 mg/kg PO q24h) may be used, but they should be tapered over 1-2 weeks to avoid adverse effects. Antibiotics are not indicated unless there is evidence of secondary infection. Supportive care includes fluid therapy in dehydrated or anorexic puppies. Nutritional supplementation with omega-3 fatty acids may have anti-inflammatory effects, but this is not well-studied. Chondroprotectants such as glucosamine and chondroitin sulfate may be used to support joint health, but their efficacy in HOD is not established. In severe cases, a constant rate infusion (CRI) of lidocaine (25-50 µg/kg/min) or ketamine (0.1-0.5 mg/kg/hr) may be used for pain management in a hospital setting. The use of gabapentin (5-10 mg/kg PO q8-12h) may be considered for neuropathic pain, but it is not routinely used. All medications should be used at the lowest effective dose for the shortest duration possible, and the puppy should be monitored for adverse effects.

The evidence-based literature on hypertrophic osteodystrophy is limited, but several studies have provided insights into the disease. A retrospective study by Bellah (1986) described the clinical and radiographic features of HOD in 12 dogs, highlighting the characteristic 'double physis' sign and the association with over-supplementation of calcium. A study by Grøndalen (1976) investigated the role of nutrition in the development of HOD and found that excessive calcium intake was a significant risk factor. More recent studies have focused on the potential role of canine distemper virus in the pathogenesis of HOD, with some case reports documenting the presence of viral antigens in affected bone. However, a causal relationship has not been established. A study by Demko and McLaughlin (2005) reviewed the current understanding of HOD and recommended a conservative approach to treatment, with NSAIDs and supportive care being the mainstay. There are no prospective randomized controlled trials evaluating different treatment protocols for HOD, and the evidence is largely based on case series and expert opinion. The ACVS and ECVS have published consensus statements on the management of developmental orthopedic diseases, but they do not specifically address HOD. Overall, the literature supports the importance of nutritional management and symptomatic treatment, and the prognosis is generally good with appropriate care. Further research is needed to elucidate the pathogenesis and optimal treatment of HOD.